Outcome of COVID-19 in Patients with Mantle Cell Lymphoma—Report from the European MCL Registry

Marie Kristin Tilch (1) , Carlo Visco (2) , Sandra Bašić Kinda (3) , Olivier Hermine (4) , Milena Kohn (5, 6) , Caroline M. Besson (6, 5) , Sylvain Lamure (7, 8) , Rémy Duléry (9) , Simone Ragaini (10) , Toby Andrew Eyre (11) , Tom van Meerten (12) , Anke Ohler (1) , Steffen Eckerle (1) , Martin H. Dreyling , Geoŗge R. Hess (1) , Eva Giné (13) , Maria Gomes da Silva

1 University Medical Center of the Johannes Gutenberg-University Mainz
2 UNIVR - Università degli studi di Verona = University of Verona
3 University Hospital Centre Zagreb
4 Hôpital Necker - Enfants Malades [AP-HP]
5 CHV - Centre Hospitalier de Versailles André Mignot
6 UVSQ - Université de Versailles Saint-Quentin-en-Yvelines
7 IGMM - Institut de Génétique Moléculaire de Montpellier
8 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
9 CRSA - Centre de Recherche Saint-Antoine
10 UNITO - Università degli studi di Torino = University of Turin
11 Churchill Hospital [Breast Care Unit]
12 University of Groningen [Groningen]
13 IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer

Data on outcome of patients with mantle cell lymphoma (MCL) and COVID-19 infection are limited. The European MCL (EMCL) registry is a centralized registry of the EMCL network, collecting real-world information about treatments and disease courses. During the COVID-19 pandemic, additional data on MCL patients with COVID-19 infection were collected, aiming to identify risk factors for mortality from COVID-19. In our retrospective, multicenter, international study, we collected data from 63 MCL patients with a median age of 64 years (range, 44–84) in 9 countries with evidence of a COVID-19 infection between February 2020 and October 2021. The overall mortality rate was high (44.4%), especially in hospitalized patients (61%) and in patients with need for intensive care unit care (94%). Patients receiving rituximab had significantly poorer survival than patients not receiving rituximab (P=0.04). Our data highlight the importance of prevention strategies and underline the need for effective vaccination in this vulnerable cohort.

Domaines: Hématologie

Marie Kristin Tilch, Carlo Visco, Sandra Bašić Kinda, Olivier Hermine, Milena Kohn, et al.. Outcome of COVID-19 in Patients with Mantle Cell Lymphoma—Report from the European MCL Registry. HemaSphere, 2022, 6 (5), pp.e0711. ⟨10.1097/HS9.0000000000000711⟩. ⟨hal-03673380⟩